A Norwegian research team has found evidence suggesting that children with specific cancers may develop unusually high levels of antibodies targeting their own DNA repair proteins. These auto-antibodies could disrupt essential repair processes, raising the likelihood of cancer years later, according to a study published in Frontiers in Immunology. The discovery identifies a previously unknown mechanism where children produce aberrant antibodies against the diverse set of hundreds of proteins responsible for identifying and correcting DNA damage—a process critical for preventing genomic errors that could lead to malignancy.
The findings emerged from an analysis of blood and tumor samples taken from 175 adults and children diagnosed with sarcoma or acute lymphoblastic leukemia between 2014 and 2017. The study compared these samples with those from healthy controls, including blood donors and children participating in the Bergen Growth Study.
When compared to healthy controls, children aged 2 to 19 with cancer exhibited markedly raised levels of IgG-class antibodies against critical DNA repair proteins, including RAD52, NUMA1, ALKBH7, APBB1, UNG, and MGMT, none of which showed mutations in their tumors. These proteins are all key components of the DNA repair machinery, yet their disruption through antibody binding rather than genetic alteration suggests an immune-mediated pathway for cancer development.
Unlike adult cancers, which typically arise from prolonged DNA damage accumulation due to environmental stressors, lifestyle factors, and aging, pediatric cancers often involve fewer mutations and affect less mature cells, such as stem or progenitor cells. The study proposes that these auto-antibodies may impair repair functions in a manner resembling inherited genetic defects associated with cancer susceptibility. Laboratory tests demonstrated that the antibodies penetrated cells, particularly during division, and bound to the TIGER organelle, where vital proteins are synthesized and modified. The authors concluded that this cellular targeting provides a plausible mechanism for increased DNA damage accumulation, potentially leading to cancer development.
The researchers then examined samples from 59 school-aged children in the British Avon Longitudinal Study of Parents and Children and Born in Bradford cohorts. Half of these children had developed cancer years later (but before the age of 30 years), while the other half had not. Those who later developed cancer were roughly eight times more likely to have antibodies against DNA repair proteins at the time of sampling, an average of six years before diagnosis. This finding shows the potential for early biomarkers of pediatric cancer risk, even in the absence of detectable genetic mutations.
Leave a Reply